IL stock · Healthcare sector · Drug Manufacturers—Specialty & Generic
Company Logo

Teva Pharmaceutical Industries Limited

TEVANYSE

8.47

USD
+0.16
(+1.93%)
Market Closed
27.48P/E
3Forward P/E
1.06P/E to S&P500
9.405BMarket CAP
- -Div Yield
Upcoming Earnings
- -
Shares Short
4/29/22
16.89M
Short % of Float
- -
Short % of Shares Outs.
1.52%
% Held by Insiders
1.50%
% Held by Institutions
46.05%
Beta
1.18
PEG Ratio
2.37
52w. high/low
11.55/7.23
Avg. Daily Volume
9.10M
Return %
Stock
S&P 500
1 year
(22.51)
(6.46)
3 years
(28.34)
36.32
5 years
(71.81)
63.92
Scale: |
High
Low
47.14
30.81
50.00
35.89
56.88
41.05
64.95
46.99
57.08
35.00
46.65
36.63
41.74
36.26
58.95
39.64
72.31
54.17
65.92
34.57
38.31
10.85
25.96
14.59
20.21
6.07
13.76
6.25
13.30
7.73
10.50
7.23
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
11.12
12.25
14.21
15.94
17.99
20.58
23.30
23.93
23.77
22.98
22.94
22.03
18.47
15.48
15.21
14.50
12.36
Earnings per share
0.72
2.54
0.81
2.29
3.72
3.10
2.25
1.49
3.58
1.86
0.34
(16.01)
(2.11)
(0.92)
(3.64)
0.38
0.31
FCF per share
2.21
1.65
3.27
3.04
3.82
3.46
3.98
2.60
4.92
5.58
4.53
2.59
1.76
0.20
0.58
0.22
0.53
Dividends per share
0.30
0.39
0.50
0.61
0.75
0.90
0.98
1.28
1.36
1.35
1.63
1.14
0.02
0.05
- -
- -
- -
CAPEX per share
0.52
0.71
0.87
0.82
0.79
1.18
1.27
1.21
1.09
0.90
0.94
0.86
0.64
0.48
0.53
0.51
0.52
Book Value per sh.
14.74
17.87
20.90
22.04
24.49
24.94
26.11
26.58
27.33
34.82
34.91
17.09
14.40
12.81
9.16
9.39
9.37
Comm.Shares outs.
756
768
780
872
896
890
872
849
853
855
955
1,016
1,021
1,091
1,095
1,095
1,103
Avg. annual P/E ratio
50.5
15.9
55.4
21.1
14.8
14.7
18.5
26.1
14.4
33.1
148.0
(1.6)
(10.0)
(12.6)
(2.9)
26.5
27.5
P/E to S&P500
2.8
0.9
2.6
0.3
0.7
0.9
1.2
1.5
0.8
1.7
6.7
(0.1)
(0.4)
(0.5)
(0.1)
0.9
1.1
Avg. annual div. yield
0.8%
1.0%
1.1%
1.3%
1.4%
2.0%
2.3%
3.3%
2.6%
2.2%
3.2%
4.3%
0.1%
0.4%
- -
- -
- -
Revenue (m)
8,408
9,408
11,085
13,899
16,121
18,312
20,317
20,314
20,272
19,652
21,903
22,385
18,854
16,887
16,658
15,879
13,633
Operating margin
9.5%
25.5%
10.3%
17.3%
24.0%
17.0%
10.9%
8.1%
19.5%
17.1%
9.8%
(78.1)%
(8.7)%
(2.6)%
(21.4)%
10.8%
8.2%
Depreciation (m)
431
521
493
908
977
1,069
1,708
1,642
1,508
1,308
1,524
2,112
1,842
1,722
1,557
1,330
1,277
Net profit (m)
546
1,952
635
2,000
3,331
2,759
1,963
1,269
3,055
1,588
329
(16,265)
(2,150)
(999)
(3,990)
417
340
Income tax rate
22.0%
16.9%
22.4%
7.5%
7.8%
4.3%
(7.5)%
(3.4)%
16.2%
27.0%
63.2%
10.5%
7.5%
22.0%
3.8%
32.1%
- -
Net profit margin
6.5%
20.7%
5.7%
14.4%
20.7%
15.1%
9.7%
6.2%
15.1%
8.1%
1.5%
(72.7)%
(11.4)%
(5.9)%
(24.0)%
2.6%
2.2%
Working capital (m)
3,569
4,488
2,945
4,539
2,348
606
3,467
1,755
2,107
5,393
(1,558)
(2,539)
(528)
(210)
(159)
1,546
838
Long-term debt (m)
4,585
3,347
5,537
4,311
4,110
10,236
11,712
10,387
8,566
8,383
32,524
28,829
26,700
24,997
23,210
22,033
393
Equity (m)
11,142
13,724
16,300
19,222
21,947
22,195
22,768
22,565
23,313
29,769
33,337
17,359
14,707
13,972
10,026
10,278
10,260
ROIC
3.3%
10.8%
3.6%
8.5%
12.5%
8.0%
6.2%
4.5%
9.7%
4.4%
0.7%
(30.2)%
(2.9)%
(0.7)%
(8.4)%
2.9%
- -
Return on capital
3.4%
10.0%
3.5%
7.1%
10.1%
6.1%
4.3%
3.2%
8.5%
4.6%
1.5%
(25.0)%
(2.4)%
(0.7)%
(6.4)%
3.3%
2.2%
Return on equity
4.9%
14.2%
3.9%
10.4%
15.2%
12.4%
8.6%
5.6%
13.1%
5.3%
1.0%
(93.7)%
(14.6)%
(7.2)%
(39.8)%
4.1%
3.3%
Plowback ratio
58.1%
84.7%
38.9%
73.6%
79.9%
71.0%
56.4%
14.2%
62.2%
27.3%
(373.6)%
107.1%
101.0%
105.2%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
17.0%
18.8%
15.2%
19.9%
22.4%
55.1%
58.1%
71.9%
39.4%
(35.6)%
28.4%
- -
- -
- -
- -
- -
- -
Capital Structure
31 Mar · 2022 | Q1
All numbers in millions
Total liabilities
$ 36,799
Total assets
$ 47,059
Long-term debt
$ 393
Cash and equiv.
$ 2,175
Goodwill
$ 19,986
Retained earnings
$ (10,529)
Common stock
1,103
Enterprise Value
$ 7,623
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
1,975
2,177
2,165
Receivables
5,676
4,581
4,529
Inventory
4,422
4,403
3,818
Other
1,391
2,046
2,251
Current assets
13,464
13,005
12,573
Acc. Payable
1,718
1,756
1,686
Debt due
2,345
3,188
1,426
Other
9,611
8,220
7,915
Current liabilities
13,674
13,164
11,027
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(4.68)%
(8.06)%
(2.43)%
Cash flow
(63.01)%
0.92%
2.53%
Earnings
(110.45)%
12.16%
(557.45)%
Dividends
- -
- -
- -
Book value
2.51%
(11.50)%
(5.76)%
Insider Trading
Type
Shares
Date
Fridriksdottir Hafrun
Sale
130,000
05/17/22
Stark David Matthew
Exempt
20,199
03/07/22
Stark David Matthew
Award
127,345
03/07/22
Stark David Matthew
Exempt
13,930
03/07/22
Stark David Matthew
Exempt
37,939
03/07/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
4,357
3,870
3,978
4,452
16,657
2021
3,982
3,910
3,886
4,100
15,878
2022
1,737
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.06
0.13
(3.97)
0.14
(3.64)
2021
0.07
0.19
0.27
(0.15)
0.38
2022
- -
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—Specialty & Generic
CEO:
Mr. Kre Schultz
Full-time employees:
34,713
City:
Petah Tikva
Address:
5 Basel Street
IPO:
Feb 11, 2013
Website:
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Recent News
· 18 Apr, 2022 · The Wall Street Journal
· 31 Dec, 2021 · The Wall Street Journal